Sun Pharmaceutical

NSE: SUNPHARMA · Pharma

₹1,781.50

▲ +1.80%

HOLD

Illustrative research · not investment advice Demo price · quote unavailable · Fundamentals and research: sample dataset (30 Oct 2026)

Price chart

Illustrative price history · not actual market candles

A. Company overview

Largest Indian pharma company with specialty and generics portfolio.

Market cap

₹3,08,03,986 Cr

Industry / Sector

Pharma

Segments

Website

Visit ↗

India FormulationsUS SpecialtyEmerging Markets

B. Fundamental analysis (illustrative)

Revenue growth

+21.33%

Net profit growth

-1.26%

Operating margin

16.45%

EBITDA margin

20.25%

ROE

22.33%

ROCE

25.3%

Debt / Equity

0.13

EPS

₹32.14

Operating cash flow

₹1,51,000 Cr

Working capital

₹78,226 Cr

5-year revenue & profit (₹ Cr)

C. Financial statements (illustrative)

₹ Cr	FY22	FY23	FY24	FY25	FY26
Revenue	5,75,293	6,41,190	7,48,180	8,35,770	9,77,829
EBITDA	1,50,240	1,52,763	1,70,752	1,78,353	1,97,973
Net profit	93,900	95,477	1,06,720	1,11,471	1,23,733
EPS (₹)	22.5	25.07	27.64	30.21	32.78

D. Valuation analysis

P/E

55.43

P/B

3.1

EV/EBITDA

32.44

Price/Sales

7.44

EPS

₹32.14

Dividend yield

0.38%

Peer comparison — Pharma

Company	CMP	P/E	P/B	ROE	D/E
Sun Pharmaceutical	1,781.5	55.43	3.1	22.33%	0.13
Dr. Reddy's Laboratories	1,276.25	54.23	4.39	18.22%	1.24
Cipla	1,489.5	36.69	3.85	10.69%	1.42
Divi's Laboratories	6,383.65	23.57	3.34	29.57%	0.89

E. Technical analysis

RSI (14)

71.44

MACD

-1.57

Support

₹1,692.43

Resistance

₹1,888.39

Volume

1,82,83,389

Illustrative technical charts · not actual market history

Candlestick (last 50 sessions)

Price with 50-DMA & 200-DMA, volume

Fibonacci retracement levels

23.6% · ₹2107.51

38.2% · ₹2041.28

50.0% · ₹1987.74

61.8% · ₹1934.21

F. Shareholding pattern

Promoter28.5%

FII9.6%

DII11.23%

of which Mutual Funds4.88%

Public50.67%

G. SWOT analysis

Strengths

Established position in Pharma
ROE of 22.33% in demo data

Weaknesses

Limited pricing power in some segments
Cyclical exposure

Opportunities

Domestic demand growth
Expansion in India Formulations

Threats

Regulatory changes
Competitive intensity

Illustrative template points for demonstration.

H. Research conclusion

Financial strength

Conservative balance sheet

Business quality

High capital efficiency

Valuation

Premium valuation

Growth

Sales growth of 21.33%

Risk assessment

Medium risk

Overall

Illustrative HOLD opinion · target ₹1,866.31 · stop loss ₹1,585.89

I. Corporate actions

Dividend history (₹/share)

Year	Dividend
FY22	5.42
FY23	5.82
FY24	6.23
FY25	6.63
FY26	7.04

Bonus, splits & announcements

Bonus history: none in demo dataset
Stock split history: none in demo dataset
Board meeting for quarterly results — demo announcement